Urology News and Research

Latest Urology News and Research

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

The Procter & Gamble Company and Warner Chilcott plc today announced an agreement for the sale of P&G's global pharmaceuticals business to Warner Chilcott for an up-front cash payment of $3.1 billion.

24 Aug 2009

Study reveals that increased neurostimulation market offers growth for device industries

The device industry would do well to focus on the treatment needs of individuals suffering from nerve-related disorders as implanted technologies that deliver electrical stimulation begin to supplant drugs for treating certain nerve-related disorders.

24 Aug 2009

FDA issues complete response letter regarding the NDA for carisbamate

The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc.

23 Aug 2009

Results of PCF funded study could impact the standard of care for prostate cancer patients

Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).

21 Aug 2009

New findings to prevent urinary tract infections

Researchers at Duke University Medical Center may have a new way to stop and even prevent the urinary tract infections (UTIs) that plague more than a third of all adults, some of them repeatedly.

21 Aug 2009

Physician shortage limits even insured patients' access to care

CBS News reports that just having insurance coverage "doesn't guarantee access" to health care, because there is s shortage of primary care doctors to provide treatment. "Baystate Medical Center is the second busiest emergency room in Massachusetts. They treat over 100,000 patients a year, but here's the thing: according to Dr. Niels Rathlev, who runs the ER, a quarter of them don't need his services." Rathlev says it would be "more appropriate" for those people to see a primary care doctor. "'The majority of patients who are frequent utilizers of the emergency department actually have insurance,' Rathlev said. 'They have a primary care physician, but they choose to come to the ER because they don't have access.'"

20 Aug 2009

Health Informatics Consulting to oversee practice management & EHR implementation at New Jersey ambulatory centers

Two new ambulatory surgical centers under construction in Northern New Jersey will streamline and improve the quality of care for patients through a partnership with Health Informatics Consulting (http://www.hi-consulting.net), a leader in healthcare technology.

20 Aug 2009

Intracacies of doctors' fees difficult to unravel

"For the most part, doctor fees are a mystery. If people see a doctor who is part of their insurance network, they are responsible only for deductibles and co-payments, and the price the health insurer pays is often a secret," The New York Times reports. "And if people see a doctor outside their network, they usually have no idea what the charge will be - even though they are responsible for most of it - until the bill comes."

19 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Watson Pharmaceuticals offers unsecured notes up to $850 million

Watson Pharmaceuticals, Inc. (NYSE: WPI), a specialty pharmaceutical company, today announced that it is offering up to $850 million aggregate principal amount of five and ten year senior unsecured notes in a registered public offering.

19 Aug 2009

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

17 Aug 2009

Obesity leads to worse prostate cancer in both black and whites equally

A new look at a large database of prostate cancer patients shows that obesity plays no favorites when it comes to increasing the risk of recurrence after surgery: Being way overweight is equally bad for blacks and whites, say researchers at Duke University Medical Center.

13 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Researchers launch study into search-and-destroy antigen for deadly skin cancer

UT Southwestern Medical Center researchers are studying a new antigen to see whether it can track down and kill cancer cells in patients with recurring melanoma, the leading cause of skin cancer deaths.

11 Aug 2009

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Prostate Cancer Early Detection incorporating the results of the recent ERSPC trial that assessed the benefit of PSA screening. The NCCN Guidelines contend that PSA screening does save lives when performed intelligently in men at high-risk of developing the disease.

11 Aug 2009

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

11 Aug 2009

Watson recalls one lot of Fentanyl transdermal system

Watson Pharmaceuticals has announced that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies.

9 Aug 2009

Discovery of cells responsible for bladder cancer spread

Johns Hopkins scientists have tracked down a powerful set of cells in bladder tumors that seem to be primarily responsible for the cancer's growth and spread using a technique that takes advantage of similarities between tumor and organ growth. The findings, reported in the July Stem Cells, could help scientists develop new ways of finding and attacking similar cells in other types of cancer.

6 Aug 2009

Tips to avoid heat stroke

The first sign of dangerous heat stroke can be just that – no sweat. As the temperature rises, your body’s natural cooling mechanism, sweat (or more kindly, perspiration), evaporates and helps to cool your body. But on those hot, humid cut-the-air-with-a knife days, evaporation is slowed and your body may not be able to keep itself cool.

5 Aug 2009

Seed implants suitable prostate cancer treatment for men of all ages

Men diagnosed with prostate cancer have a number of treatments to choose from, but it's a daunting task to figure out the right mix of therapies for an individual patient.

3 Aug 2009

Urology News and Research

Latest Urology News and Research

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

Study reveals that increased neurostimulation market offers growth for device industries

FDA issues complete response letter regarding the NDA for carisbamate

Results of PCF funded study could impact the standard of care for prostate cancer patients

New findings to prevent urinary tract infections

Physician shortage limits even insured patients' access to care

Health Informatics Consulting to oversee practice management & EHR implementation at New Jersey ambulatory centers

Intracacies of doctors' fees difficult to unravel

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Watson Pharmaceuticals offers unsecured notes up to $850 million

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

Obesity leads to worse prostate cancer in both black and whites equally

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Researchers launch study into search-and-destroy antigen for deadly skin cancer

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Watson recalls one lot of Fentanyl transdermal system

Discovery of cells responsible for bladder cancer spread

Tips to avoid heat stroke

Seed implants suitable prostate cancer treatment for men of all ages

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Urology News and Research

Latest Urology News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in